New regimens based on two or more novel agents are sought in order to shorten or simplify the treatment of both drug-susceptible and drug-resistant forms of tuberculosis. PA-824 is a nitroimidazo-oxazine now in phase II trials and has shown significant early bactericidal activity alone and in combination with the newly approved agent bedaquiline or with pyrazinamide with or without moxifloxacin...

in Children. 2nd Edn. WHO/HTM/TB/2014.03. Geneva, World Health Organization, 2014. http://apps.who.int/ medicinedocs/documents/s21535en/s21535en.pdf 6 Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016; 20: 177–186. 7 Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline a...

Tuberculosis (TB) remains the single most infectious disease causing the highest mortality in humans. India is the highest TB burden country according to World Health Organization (WHO) statistics for 2011. The previous studies in India showed that 3% of multi drug resistant TB (MDR-TB) is seen in new tuberculosis cases and 17.2% among retreatment cases. The alarming increase in MDR-TB and the ...

n engl j med 371;8 nejm.org august 21, 2014 689 regimen is not otherwise available.1 One complexity facing the FDA in reviewing the bedaquiline marketing application was that in one of the phase 2 studies, there were more deaths among patients who had bedaquiline added to a background antimycobacterial drug regimen than among those who had placebo added to the same regimen, despite relatively c...

Analogues of bedaquiline where the phenyl B-unit was replaced with monocyclic heterocycles of widely differing lipophilicity (thiophenes, furans, pyridines) were synthesised and evaluated. While there was an expected broad positive correlation between lipophilicity and anti-TB activity, the 4-pyridyl derivatives appeared to have an additional contribution to antibacterial potency. The majority ...

Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.

Abstract Background Disseminated Mycobacterium marinum infections occur rarely, in immunocompromised patients. Treatment with a prolonged multi-drug regimen exposes patients to drug–drug interactions and side effects. Case report We case of disseminated M. infection 54-year-old renal transplant, HIV-infected woman. Manifestations the were cutaneous subcutaneous nodules, mediastinal lymph nodes ...

The World Health Organization estimates that 450,000 cases of drug-resistant (DR) tuberculosis (TB) occurred worldwide in 2012. In South Africa, over 15,000 cases were diagnosed. Over half of patients in South Africa with TB are HIV co-infected. The management of drug-resistant TB is complex, prolonged, costly, associated with multiple toxicities and thus difficult for patients to complete. Dis...

Objectives: This study aimed to assess the interim outcomes for drug-resistant tuberculosis (DR-TB) patients treated with bedaquiline regimen under operational research conditions compared DR-TB without in their regimen, and describe adverse events that occurred among Philippines. Design: Patients who were a bedaquiline-containing from June 2016 May 2017 included this as intervention group, whi...

ObjectivesTo determine the safety and efficacy of bedaquiline for Chinese patients with multidrug-resistant tuberculosis (MDR-TB) based on serum concentration monitoring to identify factors associated QTc prolongation occurring during treatment.MethodsData were collected from 35 who received treatment regimens containing MDR-TB May 2018 December 2020. Blood samples collected, concentrations mea...